Immutep Limited (ASX:IMM) Reports Q3 FY25 Milestones and Financial Position
Immutep Limited (ASX:IMM) announces significant clinical trial milestones and maintains a robust cash position in its Q3 FY25 report.
Immutep Limited (ASX:IMM) announces significant clinical trial milestones and maintains a robust cash position in its Q3 FY25 report.
NOVONIX (ASX:NVX) appoints Michael O’Kronley as CEO, marking a significant leadership change within the company.
Orthocell (ASX:OCC) receives Thai FDA approval to launch Remplir™, expanding into the US$84 million nerve repair market.
Lynas Rare Earths Ltd (ASX:LYC) reports Q1 FY25 sales revenue of A$123m and initiates production of Dysprosium, reinforcing its strategic position in the rare earths market.
Surefire Resources NL (ASX:SRN) extends Yidby gold mineralisation, advances copper systems, secures offtake agreement, and receives R&D rebate.
Future Battery Minerals (ASX:FBM) announces key gold targets at Kal North and expands Western Australia landholdings, enhancing exploration prospects.
Australian Rare Earths Limited (ASX:AR3) finalises farm-in agreement for EL6678, expanding its Overland Uranium Project with promising exploration results.
Perpetual Resources (ASX:PEC) reports exceptional high-grade lithium and caesium assays at the Igrejinha Project, preparing for its maiden drill campaign in June.
Livium Ltd (ASX:LIT) signs a A$5M recycling agreement with Sell & Parker, boosting its revenue and growth prospects.
Evion Group NL (ASX:EVG) secures community support for the Maniry Graphite Mine and advances toward final environmental approvals.